Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
COMPLETED
NCT03746535
EARLY_PHASE1
Cardiovascular Disease Risk in Women With Endometriosis
Sponsor: Yale University
View on ClinicalTrials.gov
Summary
To test the hypothesis that estrogen suppression impairs endothelial dysfunction in endometriosis.
Official title: Mechanisms and Interventions Addressing Accelerated Cardiovascular Disease Risk in Women With Endometriosis
Key Details
Gender
FEMALE
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
21
Start Date
2022-07-01
Completion Date
2025-05-27
Last Updated
2026-10-16
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
Elagolix
Elagolix, 400 mg/day oral, 2X200 mg tablets/day for 4 days.
Locations (1)
Yale School of Medicine
New Haven, Connecticut, United States